Trial reportNature communications2026
Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study.
Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724851 (A Phase 1b/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with Pembrolizumab in Patients with Metastatic or Locally Advanced Colorectal or Gastric Cancer/ Gastroesophageal Junction Adenocarcinoma), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with Pembrolizumab in Patients with Metastatic or Locally Advanced Colorectal or Gastric Cancer/ Gastroesophageal Junction Adenocarcinoma
Who cites it
1 citing paper in PubMed.
- Cell differentiation-related signaling pathways: biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multicenter, open-label, single-arm, phase Ib/IIa study (NCT03724851) evaluated vactosertib plus pembrolizumab in patients with non-microsatellite instability-high (non-MSI-high) metastatic colorectal cancer (mCRC) or gastric cancer (mGC). The study included dose-escalation and expansion phases. Vactosertib was administered five days per week at predefined dose levels in combination with pembrolizumab (200 mg intravenously every three weeks). The primary outcome was safety and tolerability; the combination demonstrated a manageable safety profile; prespecified secondary outcomes included pharmacokinetics and anti-tumor activity, including objective response rate, duration of response, time to response, progression-free survival, and overall survival; pharmacodynamic biomarkers were evaluated as exploratory outcomes. A total of 120 patients were included in the safety analysis (mCRC: 108, mGC: 12) and 115 in the efficacy analysis (mCRC: 103, mGC: 12). Treatment-related adverse events occurred in 70.8% of patients, with pruritus and rash being the most common. In mCRC, the objective response rate was 12.6%, with higher responses in patients without liver metastases (22.5%) than in patients with liver metastases (6.3%) by RECIST v1.1. The median overall survival was 13.2 months. No objective responses were observed in mGC. Vactosertib plus pembrolizumab showed clinical activity in non-MSI-high mCRC, particularly in patients without liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.